Gene-editing therapies for the nervous system may need at least another round of studies before they are safe enough to enter human trials, according to one of the world’s most influential figures in the commercialisation of brain science.
“The techniques are reasonably well established for animal experiments, but they really haven’t been as mature for human studies,” said Karoly Nikolich, an adjunct professor at Stanford University School of Medicine, in an exclusive interview with the South…

Read More